Although the specific molecular mechanism of CDKN2A regulation is still unclear, which may be related to p53 protein, CDKN2A is expected to become a target of HCC treatment in view of its important role in the occurrence and development of HCC. The gene discussed is TP53; the disease is hepatocellular carcinoma.